CurrentBlue Cross Blue Shield - TexasPolicy CPCPLABOO3

Vitamin D Testing (25‑hydroxyvitamin D and 1,25‑dihydroxyvitamin D) Coverage and Reimbursement Criteria

Customize your policy alerts

Sign up for Blue Cross Blue Shield - Texas Policy CPCPLABOO3 alerts

Get alerted when Policy CPCPLABOO3 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Coverage and reimbursement criteria for serum vitamin D testing (25-hydroxyvitamin D and 1,25-dihydroxyvitamin D) for members of Blue Cross Blue Shield of Texas; applies to providers submitting claims for laboratory vitamin D tests.

Policy Summary

PayerBlue Cross Blue Shield - Texas

PolicyVitamin D Testing (25‑hydroxyvitamin D and 1,25‑dihydroxyvitamin D) Coverage and Reimbursement Criteria

Policy CodePolicy CPCPLABOO3

Change TypeClarification / Literature review

Effective DateMay 15, 2025

Last ReviewFeb 5, 2025

Next Review Date

Key ActionDocument clinical indication(s) when ordering vitamin D tests and confirm applicable procedure codes and prior authorization requirements with the member's plan.

SourceLink

POLICY UPDATE CHANGES

Edited reimbursement Information item #3 for clarity and consistency and revised references after literature review.

2test types addressed

12 weeks

OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

CurrentBlue Cross Blue Shield - TexasPolicy CPCPLABOO3

Vitamin D Testing (25‑hydroxyvitamin D and 1,25‑dihydroxyvitamin D) Coverage and Reimbursement Criteria

Customize your policy alerts

Sign up for Blue Cross Blue Shield - Texas Policy CPCPLABOO3 alerts

Get alerted when Policy CPCPLABOO3 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Policy Summary

PayerBlue Cross Blue Shield - Texas

PolicyVitamin D Testing (25‑hydroxyvitamin D and 1,25‑dihydroxyvitamin D) Coverage and Reimbursement Criteria

Policy CodePolicy CPCPLABOO3

Change TypeClarification / Literature review

Effective DateMay 15, 2025

Last ReviewFeb 5, 2025

Next Review Date

Key ActionDocument clinical indication(s) when ordering vitamin D tests and confirm applicable procedure codes and prior authorization requirements with the member's plan.

SourceLink

POLICY UPDATE CHANGES

Edited reimbursement Information item #3 for clarity and consistency and revised references after literature review.

2test types addressed

12 weeks

Coverage Criteria for Vitamin D Testing

Indications for 25‑hydroxyvitamin D testing

25‑hydroxyvitamin D testing may be reimbursable when ANY of the following clinical circumstances apply (indications from Note 1):

Indications for 25‑hydroxyvitamin D testing: Biliary cirrhosis and other specified disorders of the biliary tract; celiac disease; blind loop syndrome; coronary artery disease when consideration of chronic vitamin D and calcium therapy is relevant; eating disorders; dermatomyositis; candidates for or recipients of bariatric procedures (e.g., Roux‑en‑Y gastric bypass, sleeve gastrectomy, biliopancreatic diversion with or without duodenal switch); hyperparathyroidism or hypoparathyroidism; hypercalcemia, hypocalcemia, or other disorders of calcium metabolism; individuals receiving hyperalimentation; inflammatory bowel disease (Crohn disease and ulcerative colitis); intestinal malabsorption; liver cirrhosis; long‑term use of anticonvulsants, glucocorticoids, or other medications known to lower vitamin D levels; malnutrition; myopathy related to endocrine disease; myalgia and other myositis; neoplastic hematologic disorders; osteomalacia; osteogenesis imperfecta; osteopetrosis; osteoporosis; pancreatic steatorrhea; primary or miliary tuberculosis; psoriasis; regional enteritis; renal/ureteral/urinary calculus; rickets; sarcoidosis; stage III–V chronic kidney disease and end‑stage renal disease; systemic lupus erythematosus; and other conditions listed in Note 1.

Full list in Note 1.

Indications for 1,25‑dihydroxyvitamin D testing

1,25‑dihydroxyvitamin D testing may be reimbursable when ALL of the following apply (indications from Note 2):

Indications for 1,25‑dihydroxyvitamin D testing: Disorders of calcium metabolism; familial hypophosphatemia; Fanconi syndrome; hyperparathyroidism or hypoparathyroidism; individuals receiving hyperalimentation; neonatal hypocalcemia; osteogenesis imperfecta; osteomalacia; osteopetrosis; primary or miliary tuberculosis; renal/ureteral/urinary calculus; rickets; sarcoidosis; stage III–V chronic kidney disease and end‑stage renal disease; and related conditions listed in Note 2.

Use 1,25‑dihydroxyvitamin D for evaluation of defects in vitamin D metabolism; not for routine deficiency screening.

Monitoring/Follow‑up testing

Monitoring and follow‑up testing rules for documented deficiency:

Monitoring after documented deficiency: Repeat 25‑hydroxyvitamin D testing may be reimbursable at least 12 weeks after initiation of vitamin D supplementation; testing may be performed twice per year while titrating supplementation to the therapeutic goal and annually once the therapeutic range has been achieved.12 weeks; twice per year; annual

Restrictions apply as stated in reimbursement information.

The policy distinguishes between measurement of 25‑hydroxyvitamin D and the active metabolite 1,25‑dihydroxyvitamin D. 25‑hydroxyvitamin D is the primary serum analyte used to assess vitamin D status and may be reimbursable when there is an underlying disease or condition specifically associated with vitamin D deficiency or decreased bone density, or when hypervitaminosis D is suspected. By contrast, 1,25‑dihydroxyvitamin D is reserved for evaluation of disorders of vitamin D metabolism and is not appropriate as a routine screening test for deficiency.

Routine population screening of asymptomatic individuals is not reimbursable. Specifically, the policy states that routine screening for vitamin D deficiency with serum testing in asymptomatic individuals and/or during general encounters is not covered, and that measurement of serum 1,25‑dihydroxyvitamin D to screen for vitamin D deficiency is likewise not reimbursable. Providers should document clinical indications that meet the policy criteria to support payment.

Conditions Associated with Vitamin D Deficiency / Disorders

Conditions associated with vitamin D deficiency or disorders of vitamin D metabolism (see Notes 1 and 2).

Conditions associated with vitamin D deficiency or disorders of vitamin D metabolism: Refer to Note 1 for conditions associated with vitamin D deficiency relevant to 25‑hydroxyvitamin D testing (including biliary tract disorders, celiac disease, blind loop syndrome, coronary artery disease where chronic therapy is being considered, eating disorders, dermatomyositis, bariatric surgery candidates/recipients, disorders of parathyroid function, disorders of calcium metabolism, hyperalimentation, inflammatory bowel disease, intestinal malabsorption, liver cirrhosis, long‑term use of anticonvulsants or glucocorticoids, malnutrition, endocrine myopathy, neoplastic hematologic disorders, osteomalacia, osteogenesis imperfecta, osteopetrosis, osteoporosis, pancreatic steatorrhea, tuberculosis, psoriasis, regional enteritis, renal/urinary calculi, rickets, sarcoidosis, CKD stage III–V and ESRD, systemic lupus erythematosus, and others) and to Note 2 for conditions indicating evaluation of defects in vitamin D metabolism by 1,25‑dihydroxyvitamin D (including disorders of calcium metabolism, familial hypophosphatemia, Fanconi syndrome, hyperparathyroidism/hypoparathyroidism, hyperalimentation, neonatal hypocalcemia, osteogenesis imperfecta, osteomalacia, osteopetrosis, tuberculosis, renal/urinary calculus, rickets, sarcoidosis, and CKD stage III–V/ESRD).

See Notes 1 and 2 for complete lists.

Procedure Codes and Frequency Limits

Documentation Required

inv-10: Code verification and plan rules

Providers should verify applicable procedure and diagnosis codes, confirm plan-specific coverage rules, and determine whether prior authorization is required. Ensure documentation supports medical necessity (e.g., underlying disease/condition associated with vitamin D deficiency, suspected hypervitaminosis D, documented deficiency, or disorders of vitamin D metabolism). Submit claims with the correct CPT/HCPCS and ICD-10 codes and include supporting documentation and dates of supplementation and prior testing. Routine screening in asymptomatic individuals is not reimbursable; bill accordingly.

Verify affected procedure and diagnosis codes with the member’s plan and payer guides
Confirm prior authorization requirements before performing non-emergency testing
Document clinical indication (e.g., underlying disease, suspected hypervitaminosis, documented deficiency, metabolic disorders) and include supplementation start date when submitting repeat testing claims
Do not bill for routine screening of asymptomatic individuals (not reimbursable)

Provider Responsibilities and Billing Guidance

Note

Step‑therapy / program notice

Note for providers: this policy does not specify additional step‑therapy requirements for vitamin D testing; follow plan documents or product‑specific rules if applicable.

Documentation Required

Document services and supporting clinical indications

Provide and retain accurate clinical documentation supporting the medical indication for vitamin D testing when submitting claims; claims are subject to review against benefit coverage and medical policy.

Document the clinical indication that meets policy criteria (see Note 1 or Note 2 as applicable).
Be prepared to furnish additional records upon request during claim review.

Ordering Requirements

Note

Document clinical indication(s) on orders

When ordering vitamin D tests, document the specific clinical indication(s) on the order and in the medical record; claims lacking documentation that supports medical necessity may be denied.

Include which test is ordered (25‑hydroxyvitamin D or 1,25‑dihydroxyvitamin D) and the clinical reason tied to policy indications.
Ensure coding aligns with the documented service and industry coding guidelines.

Not Covered

Not covered: Routine asymptomatic screening for vitamin D deficiency and the use of 1,25‑dihydroxyvitamin D as a screening test are explicitly excluded from reimbursement. Claims for these uses are considered not medically necessary under this policy.

Definitions

inv-15: 25‑hydroxyvitamin D — primary serum analyte used to assess vitamin D status (definition).

Definition25-hydroxyvitamin D is the primary serum analyte used to assess vitamin D status

Use casesReimbursable for individuals with underlying diseases associated with deficiency and for monitoring supplementation per policy criteria

Includes fractionsTesting may include D2 and D3 fractions as part of total 25-hydroxyvitamin D analysis

inv-16: 1,25‑dihydroxyvitamin D — active metabolite measured for disorders of vitamin D metabolism (definition).

Definition1,25-dihydroxyvitamin D is the active metabolite measured for evaluation of disorders of vitamin D metabolism

IndicationsUsed for evaluation of defects in vitamin D metabolism (see Note 2) rather than routine deficiency screening

Frequency Limits

inv-18: 25‑hydroxyvitamin D — repeat testing >=12 weeks after supplementation; twice per year during adjustment; annual maintenance.

Repeat testing intervalRepeat 25-hydroxyvitamin D testing >= 12 weeks after initiation of supplementation

Adjustment period monitoringTwice per year (semiannually) while titrating supplementation to therapeutic goal

Maintenance monitoringAnnual testing once therapeutic range achieved

Background

Background: 25‑hydroxyvitamin D measurement is the principal test for assessing vitamin D status and is reimbursable when clinical indications consistent with the policy are present (for example, underlying diseases associated with deficiency or suspicion of hypervitaminosis). In contrast, 1,25‑dihydroxyvitamin D testing is restricted to evaluation of conditions involving defects in vitamin D metabolism and is not appropriate for routine deficiency screening.